🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

RecruitingPhase 1Ages 18 Years - anyAllLebanese University
NCT06307249 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects. This clinical trial focuses on an innovative combination of two targeted inhibitors, Palbociclib and Bevacizumab, for their potential synergistic effects in addressing these challenging malignancies. Moreover, this study incorporates a molecular approach by considering Long Non-Coding RNAs (LncRNAs) as biomarkers. Initiating with a focus on colorectal cancer, the study aims to expand its scope to other solid tumors, including lung, breast, ovarian and other cancers. Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, disrupts the cell cycle progression, particularly in cancer cells with specific molecular characteristics. Bevacizumab, a vascular endothelial growth factor (VEGF) inh

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Individuals of white ethnicity. * Age between \> 18 * Both males and females. * Diagnosis of selected cancer type (e.g., colorectal cancer, lung cancer, genitourinary cancers, breast cancer). * Cancer stage III/ IV with or without metastasis or lymph node dissemination at the time of enrollment. * Unrelated patients. Exclusion Criteria: * History of hematological cancer types or previous cancers, recurrent or relapse. * Diagnosis of inflammatory bowel diseases. * Pre-existing cardiovascular diseases or coronary artery diseases. * Confirmed treated or untreated autoimmune diseases. * Metabolic disorders, diabetes, or hypertension. * Neurological diseases. * Evidence of cardiac, renal, bone, or cerebral damage. * Presence of more than one type of malignancies. * Active infections or myositis. * Familial polyposis. * Alcohol or smoking habits. * Body mass index (BMI) \>30. * Significant weight loss within the last 2 years. * History of surgeries. * Pregnancy. * Related patients.
💊

What it tests

  • SNP
  • Palbociclib 125mg
  • Bevacizumab
📍

Where

2 sites
Haykel Hospital
Tripoli, Lebanon
Lebanese University
Tripoli, Lebanon
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy